CDEK
← Mechanisms of action

Cancer/testis antigen 1

SINGLE PROTEINHomo sapiens

Linked proteins

Drugs acting on this target (34)

Active Pharmaceutical Ingredient Mechanism Type ▲ Approval Status API Type Mechanism of Action
asp0739Binding agentexperimentalmAbCancer/testis antigen 1 binding agent
alvac ny eso-1 vaccineImmunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
dec-205/ny-eso-1 fusion protein cdx-1401Immunity, activeexperimentalBiologicalCancer/testis antigen 1 immunity, active
fowlpox-ny-eso-1 vaccineImmunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
hbi 0201-esoImmunity, activeexperimentalCell therapyCancer/testis antigen 1 immunity, active
imf-001Immunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
mage-a3 and ny-eso-1Immunity, activeexperimentalBiologicalCancer/testis antigen 1 immunity, active
ny-eso-1 iscomatrixImmunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
ny-eso-1 olp4Immunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
ny-eso-1 peptidesImmunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
recombinant vaccinia-ny-eso-1 vaccineImmunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
tbi-1301Immunity, activeexperimentalCell therapyCancer/testis antigen 1 immunity, active
vsv-02Immunity, activeexperimentalVaccineCancer/testis antigen 1 immunity, active
anti-hla-a2/ny-eso-1 tcr-transduced autologous t lymphocytesImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
anti-ny eso-1 mtcr pblImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
anti-ny eso-1 t cell receptor cd62l+ cellsImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
anti-ny eso-1 t-cell receptor pblImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
autologous genetically modified t cells, ny-eso-1c259 tImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
autologous ny-eso-1-specific cd8-positive t lymphocytesImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
genetically engineered ny-eso-1-specific t lymphocytesImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
gsk3901961Immunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
il-12 & anti-ny eso1 tcr pblImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
letetresgene autoleucelImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
lv-nyeso tcr /sr39tk pbscImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
ny-eso-1 reactive tcr retroviral vector transduced autologous pblImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
ny-eso-1 t cellsImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
ny-eso-1-specific t cellsImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
ny-eso-1(157-165) peptide-pulsed autologous dendritic cell vaccineImmunity, passiveexperimentalVaccineCancer/testis antigen 1 immunity, passive
ny-eso-1(c259)t cellsImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
ny-eso-1c259-modified t cellsImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
rv-nyeso tcr pbmcImmunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
taest16001Immunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
tc-n201Immunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive
tcrt-eso-a2Immunity, passiveexperimentalCell therapyCancer/testis antigen 1 immunity, passive